newsfilter
← Earnings
Earnings Releases·

Ainos — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue surged 29,567% year-over-year to $642,889, while GAAP net loss narrowed 36% to $1,886,074 and non-GAAP adjusted net loss improved 51% to $672,352; gross margins expanded to 83.4% (GAAP) and 83.6% (non-GAAP) from 78.0% in Q3 2025.
  • Secured a $9 million follow-on agreement for 5,000 AI Nose systems and a $600,000 initial VELDONA license fee triggered by technology transfer, with management projecting $175,000 in quarterly recurring revenue starting Q4 2026.
  • Total liabilities rose to $16.6 million as of September 30, 2026, driven by a $11 million reclassification of convertible notes to current liabilities and a new $2.8 million loan, though cash equivalents increased to $660,916.
  • Management anticipates future net losses and highlights risks regarding capital raising, clinical trial advancement, and the realization of license fees, while noting subsequent collection of $950,000 in contractual payments.
Company
AINOS INC
Sector
Technology
Industry
Scientific & Technical Instruments